RCCC组织中肺癌肿瘤抑制因子1的表达变化及意义

摘要

目的 观察肾透明细胞癌(RCCC)中肺癌肿瘤抑制因子1(TSLC1)的表达变化,并探讨其临床意义.方法 采用免疫组化sP法检测40例RCCC组织及18例癌旁正常肾组织中的TSLC1.结果 RCCC中TSLC1的阳性表达率为20％,显著低于癌旁正常肾组织中的100％ (P＜0.01),有淋巴结转移者TSLC1的阳性表达率显著低于无淋巴结转移者的31.5％ (P＜0.01).TSLC1表达随着RCCC病理分期、分级的增加呈递减趋势(r=-0.300、-0.404,P均＜0.05).结论 RCCC组织中有明显的TSLC1表达缺失.TSLC1的表达与RCCC病理分期、分级有关,其表达缺失与RCCC的发生、发展有关.%Objective To detect the expression of tumor suppressor in lung cancer 1 (TSLC1) in tissues of normal human kidney and renal clear cell carcinoma ( RCCC) and explore its clinical significance. Methods The expression of TSLC1 in 40 RCCC samples and 18 pericancerous normal renal tissues were examined by immunohistochemistry SP method. Results The positive expression rate of TSLC1 in RCCC (20% ) was significantly lower than that in nearby non-tumorous tissues ( 100 % , P<0.01 ) , the positive expression of TSLC1 in RCCC with lymph node metastasis was significantly lower than that in RCCC without lymph node metastasis ( P <0.01 ). The expression of TSCL1 was significantly associated with tumor clinical stage and grade, the higher the clinical stage and grade, the lower the rate of positive expression of TSCL1 (r = - 0.300, - 0.404, all P < 0.05). Conclusions There is significant loss of expression of TSCL1 in RCCC tissues; the expression of TSLC1 showes a negative correlation with the pathological stage and grade of RCCC, the loss of expression of TSCL1 may be related to the occurrence and development of RCCC.